Andere talen BioInvent International AB

Aandelen

BINV

SE0015244520

Beurs gesloten - Nasdaq Stockholm Andere beurzen 12:59:33 30-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
26 ^SEK	+2,77%		+11,59%	+37,13%

30/04	BioInvent kondigt evaluatie van Attana-technologie aan	CI
24/04	BioInvent International AB (publ) rapporteert resultaten voor het eerste kwartaal eindigend op 31 maart 2024	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

BioInvent evaluating Attana Technology	30/04
BioInvent Announces Evaluating Attana Technology	30/04
BioStock: BioInvent selected to present at ASCO in Chicago	29/04
BioInvent International AB, Interim report January-March 2024	25/04
BioInvent Q1 2024 - Approaching Catalysts	25/04
BioInvent to Present Clinical Data from its two leading assets at ASCO 2024	24/04
BioInvent International AB: Interim report January-March 2024	24/04
BioInvent International AB Reports Earnings Results for the First Quarter Ended March 31, 2024	24/04
BioInvent International AB publishes Annual Report 2023	04/04
BioStock: BioInvent deepens collaboration with MSD	04/04
BioInvent announces a new clinical trial collaboration and supply agreement with MSD to evaluate BI-1910, the company s second anti-TNFR2 antibody in combination with KEYTRUDA	03/04
BioInvent, Merck & Co. Unit Sign Clinical Trial, Supply Deal for Tumor Treatment as Add-On Therapy for Keytruda	03/04
BioInvent International : announces a new clinical trial collaboration and supply agreement with MSD to evaluate BI-1910, the company's second anti-TNFR2 antibody in combination with KEYTRUDA® (pembrolizumab)	02/04
BioInvent announces a new clinical trial collaboration and supply agreement with MSD to evaluate BI-1910, the company’s second anti-TNFR2 antibody in combination with KEYTRUDA® (pembrolizumab)	02/04
Notice to Annual General Meeting in BioInvent International AB	27/03
BioStock: BioInvent's CEO comments on the study success in China	11/03
BioInvent International, CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed, Refractory Indolent Non-Hodgkin's Lymphoma In China	06/03
BioInvent International: CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma In China	05/03
BioInvent International: CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin’s Lymphoma In China	05/03
BioInvent International AB Year-end report January 1, December 31, 2023	23/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen BioInvent International AB

Aandelen

BINV

SE0015244520

Andere talen

Filters